Elsevier

Clinical Therapeutics

Volume 25, Issue 3, March 2003, Pages 890-903
Clinical Therapeutics

Original research
Multicenter, randomized, double-masked, parallel-group assessment of simultaneous glipizide/metformin as second-line pharmacologic treatment for patients with type 2 diabetes mellitus that is inadequately controlled by a sulfonylurea

https://doi.org/10.1016/S0149-2918(03)80112-1Get rights and content

Abstract

Background: Many patients with type 2 diabetes mellitus (DM) with inadequate long-term blood glucose control with sulfonylurea or metformin monotherapy require additional treatment. The synergistic effects of combining glipizide with metformin on glucose control may be realized by treating the primary effects of type 2 DM, impaired insulin secretion, and insulin resistance.

Objective: This study assessed therapy with glipizide/metformin combination tablets in patients with type 2 DM that is uncontrolled by at least half the maximum labeled daily dose of a sulfonylurea.

Methods: In this multicenter, double-masked, parallel-group, active-controlled study, patients were randomized to receive glipizide 30-mg, metformin 500-mg, or glipizide/metformin 5500 mg tablets for 18 weeks (metformin and glipizide/metformin doses were titrated to achieve blood glucose control). Maximum total daily doses were glipizide 30 mg, metformin 2000 mg, and glipizide/metformin 202000mg.

Results: A total of 247 patients were included in the study. The mean (SD) age was 56.2 (10.1) years; 61.5% of patients were male; 70.0% were white, 15.8% were Hispanic/Latino, 13.0% were black, and 1.2% were Asian/Pacific Islanders.

References (17)

  • R.A. DeFronzo

    Pharmacologic therapy for type 2 diabetes mellitus

    Ann Intern Med

    (1999)
  • D. Porte

    Clinical importance of insulin secretion and its interaction with insulin resistance in the treatment of type 2 diabetes mellitus and its complications

    Diabetes Metab Res Rev

    (2001)
  • D. Hawkins et al.

    National Pharmacy Cardiovascular Council treatment guidelines for the management of type 2 diabetes mellitus: Toward better patient outcomes and new roles for pharmacists

    Pharmacotherapy

    (2002)
  • Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)

    Lancet

    (1998)
  • D.R. Matthews et al.

    UKPDS 26: Sulphonylurea failure in non-insulin-dependent diabetic patients over six years. UK Prospective Diabetes Stud (UKDPS) Group

    Diabetes Med

    (1998)
  • R.C. Turner et al.

    Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: Progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group

    JAMA

    (1999)
  • I.M. Stratton et al.

    Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): Prospective observational study

    BMJ

    (2000)
  • E.M. Laska et al.

    Testing whether an identified treatment is best

    Biometrics

    (1989)
There are more references available in the full text version of this article.

Cited by (0)

View full text